- Home
- ARDX
ARDX
Ardelyx Inc.
as 11-07-2025 3:52pm EST
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | FREMONT |
| Market Cap: | 882.9M | IPO Year: | 2014 |
| Target Price: | $10.65 | AVG Volume (30 days): | 4.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.24 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.21 - $6.78 | Next Earning Date: | 10-30-2025 |
| Revenue: | $398,234,000 | Revenue Growth: | 58.12% |
| Revenue Growth (this year): | 18.9% | Revenue Growth (next year): | 31.52% |
Stock Insider Trading Activity of Ardelyx Inc. (ARDX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Williams Laura A | ARDX | Chief Patient Officer | Aug 26 '25 | Sell | $6.12 | 80,000 | $489,680.00 | 396,322 | |
| RAAB MICHAEL | ARDX | President & CEO | Aug 21 '25 | Sell | $5.93 | 45,687 | $271,001.58 | 1,502,250 | |
| Renz Justin A | ARDX | Chief Financial Officer | Aug 21 '25 | Sell | $5.93 | 7,037 | $41,741.37 | 409,052 | |
| Williams Laura A | ARDX | Chief Patient Officer | Aug 21 '25 | Sell | $5.93 | 6,261 | $37,138.37 | 396,322 | |
| Kelliher Mike | ARDX | Chief Business Officer | Aug 21 '25 | Sell | $5.93 | 5,417 | $32,132.02 | 276,741 | |
| GRAMMER ELIZABETH A | ARDX | See Remarks | Aug 21 '25 | Sell | $5.93 | 5,841 | $34,647.06 | 305,890 | |
| Foster Eric Duane | ARDX | Chief Commercial Officer | Aug 21 '25 | Sell | $5.93 | 15,308 | $90,802.46 | 301,498 |
Latest Ardelyx Inc. News
ARDX Breaking Stock News: Dive into ARDX Ticker-Specific Updates for Smart Investing
MT Newswires
8 days ago
Sector Update: Health Care Stocks Mixed Pre-Bell Friday
MT Newswires
8 days ago
Ardelyx Q3 Breakeven, Revenue Increases; Shares Rise Pre-Bell
GuruFocus.com
8 days ago
Ardelyx Inc (ARDX) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Market Challenges
Zacks
8 days ago
Ardelyx (ARDX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Zacks
8 days ago
Ardelyx (ARDX) Reports Break-Even Earnings for Q3
Associated Press Finance
8 days ago
Ardelyx: Q3 Earnings Snapshot
GlobeNewswire
9 days ago
Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
11 days ago
Ardelyx Presents Data that Continues to Support the Benefits of IBSRELA® (tenapanor) at the American College of Gastroenterology’s 2025 Annual Meeting
Compare ARDX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARDX Ardelyx Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.